Pipeline        AIM Biologicals         Macimorelin Tx           AEZS-150         Macimorelin Dx         Vaccine Platform

AIM Biologicals
Targeted Immunomodulating Therapeutics

 

AIM Biologicals (AutoImmunity Modifying Biologicals) utilize a novel mechanism which is believed to demonstrate that peptide antigens presented on immunosuppressive MHC class I molecules can selectively and efficiently induce antigen-specific tolerance. Based on this mechanism, the targeted immunomodulating therapeutics are being designed as optimized soluble molecules with the goal that they may be adapted to selectively induce tolerance to various autoantigens.

During pregnancy, the maternal immune system tolerates paternal antigens from the embryo but is still effective to protect mother and embryo from foreign antigens. Parts of the natural mechanisms responsible for this feto-maternal immune tolerance form the scientific basis for the concept of AIM Biologicals.

Targeted, highly specific, autoimmunity modifying proteins

Technology derived from body’s natural process that protects a fetus from the mother’s immune system

  • Fetal cells persist in mothers for decades after delivery and vice versa → lasting, selective immune tolerance which cannot be explained by barrier function*

* Cirello et al.; Journal of Cancer Research and Clinical Oncology 142, 2016

Developed at leading research and teaching university 
Julius-Maximilians-University Wuerzburg 

Pre-clinical studies conducted by the Julius-Maximilians-University thus far indicate that tolerance induction appears to be achieved via selective elimination of antigen-specific immune effector cells and via induction of antigen-specific regulatory T cells from naïve T cells.

The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation

Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Well-defined antigen: Aquaporin-4 (AQP4)

  • NMOSD is an auto-antibody mediated inflammatory CNS orphan disorder with significant unmet medical need affecting 1 per 100,000 people*

* Hor et al.; Frontiers in Neurology 2020

 

Parkinson’s Disease (PD)

  • Neurodegenerative movement disorder affecting over 7 million people worldwide

  • Growing evidence suggests that PD could be considered as an autoimmune disease*

  • α-Synuclein (α-Syn) described as target

* Bonam et al.; Autoimmunity Reviews 2020

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Affects

~10,000-15,000

people in the U.S. 
and E
urope

NMOSD, also known as “Devic disease”, is a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and of the spinal cord (myelitis).
 

50% of individuals will become wheelchair bound and blind
 

30% fatality within 5 years